Is Pharma at a HALT with Blogging, Sharing, Posting and Tweeting Because of the FDA’s Delay of Its Social Media Guidance?
We’re into the second quarter of 2011 and the hotly-anticipated guidance document has yet to be seen. What should the industry be expecting?
From what I can tell after checking our company’s Enterey Twitter page, Pharma social media is alive and well but under what direction are they communicating with the online community? Are they putting themselves at risk or is there opportunity that the FDA is holding them back from by delaying this process?
The FDA had been expected to issue a draft of guidelines in the first quarter of this year, but the deadline has gone and went. The purpose of these guidelines is to give the Life Sciences industries direction on how they interact and communicate through social media platforms with physicians, allied healthcare professionals and consumers due to the immense amount of information available and the potential threats that arise from this very informal line of communication.
In the Consensus Interactive presentation given back at the FDA Part 15 Public Hearing on November 15, 2009, it’s stated that the Pharma industry is at a crossroads with the modern development of Social Media. The FDA needs to act now in support of the industry taking advantage of the growth benefits and tremendous opportunities that just may be passing them by. It’s been almost two years later since the hearing.
Rohit Bhargave of 360 Digital Influence, gives a well-dressed commentary on what we can expect from the US regulator in regards to this ever changing challenge of social media and affects on the world of Pharma. For further details, read his explanation to see how this might just change your future blogging, sharing, posting and tweeting.
Published by: Tita Tavares, Enterey | Director, Brand Development
Next week’s blog:
Facility Start up in Biotech